6955.HK
BOAN BIOTECH
HK$5.82
+1.57%
2026-06-01
About BOAN BIOTECH
Shandong Boan Biotechnology Co., Ltd., a biopharmaceutical company, develops, manufactures, and markets biologics in Mainland China. The company offers Boyounuo (BA1101), an anti-VEGF humanized monoclonal antibody injection for mCRC, advanced metastatic or recurrent non-small cell lung cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, primary peritoneal cancer, cervical cancer, and hepatocellular carcinoma indications; Boyoubei (BA6101), a human immunoglobulin G2 monoclonal antibody of the RANK ligand for the treatment of postmenopausal and male osteoporosis; and Boluojia (BA1102), a fully human IgG2 anti-RANKL monoclonal antibody to treat bone metastases from solid tumors, and giant cell tumor of bone. It also develops BA5101, a long-acting glucagon-like peptide-1 receptor agonist intended for glycemic control in adults with type 2 diabetes; BA9101, a recombinant human vascular endothelial growth factor receptor antibody fusion protein ophthalmic injection; BA1104, a monoclonal antibody in Phase 3 clinical trial that can enhance the immune response of T cells against tumors by preventing the programmed cell death 1 receptor; BA2101, a long-acting human monoclonal antibody of the IgG4 subtype in Phase 1b/2 trial that targets interleukin-4 receptor subunit a; BA1106, a non-IL-2 blocking anti-CD25 antibody in Phase 1b/2 trial; BA1301, an ADC candidate in Phase 1b/2 trial that targets Claudin 18.2; BA1202, a bi-specific antibody drug in Phase 1a trial that targets CEA/CD3; and BA1302, a CD228-directed ADC in Phase 1a trial. It has an agreement with the Zencore Biologics Co., Ltd. to use its stable cell line development platform non-exclusively, BA-HIEXcell for the development of antibodies and therapeutic proteins. The company was founded in 2013 and is headquartered in Yantai, China. Shandong Boan Biotechnology Co., Ltd. is a subsidiary of Shandong Luye Pharmaceutical Co., Ltd.
Key Fundamentals
P/E Ratio
573.00
Forward P/E
14.24
EPS (TTM)
HK$0.01
ROE
0.3%
Revenue Growth (YoY)
7.7%
Profit Margin
0.9%
Debt/Equity
28.59
Price/Book
1.13
Beta
0.05
Market Cap
HK$3.57B
Avg Volume (10D)
12.7M
Recent Breakout Signals
No recent breakout signals detected for 6955.HK.
Recent Price Range (60 Days)
60D High
HK$8.94
60D Low
HK$5.60
Avg Volume
6.1M
Latest Close
HK$5.82
Get breakout alerts for 6955.HK
Sign up for Breakout Scanner to receive daily notifications when 6955.HK triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
BOAN BIOTECH (6955.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 6955.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 6955.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.